BioCentury | Jun 24, 2013
Company News

Aurigene, Debiopharm deal

...be reached in time for publication. In March 2011, Debiopharm received exclusive, worldwide rights to Debio 1142...
BioCentury | Jul 23, 2012
Product Development

Debio's dual deal

...tumors. Debiopharm licensed it from Ascenta Therapeutics Inc. last September. Earlier last year, Debiopharm licensed Debio 1142...
BioCentury | Apr 25, 2011
Company News

Aurigene, Debiopharm S.A. deal

...Last month, Debiopharm received exclusive, worldwide rights to Debio 1142 from Aurigene. The compound is an inhibitor...
Items per page:
1 - 3 of 3